Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan

As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers. We collected data on participants' sociodemographic characteristics, contact beha...

Full description

Saved in:

Bibliographic Details
Published in	Global Health & Medicine Vol. 5; no. 1; pp. 5 - 14
Main Authors	Shimbashi, Reiko, Shiino, Teiichiro, Ainai, Akira, Moriyama, Saya, Arai, Satoru, Morino, Saeko, Takanashi, Sayaka, Arashiro, Takeshi, Suzuki, Motoi, Matsuzawa, Yukimasa, Kato, Kenichiro, Hasegawa, Mitsuru, Koshida, Rie, Kitaoka, Masami, Ueno, Takafumi, Shimizu, Hidefumi, Yuki, Hiroyoshi, Takeda, Tomoko, Nakamura-Uchiyama, Fukumi, Takasugi, Kashiya, Iida, Shun, Shimada, Tomoe, Kato, Hirofumi, Fujimoto, Tsuguto, Iwata-Yoshikawa, Naoko, Sano, Kaori, Yamada, Souichi, Kuroda, Yudai, Okuma, Kazu, Nojima, Kiyoko, Nagata, Noriyo, Fukushi, Shuetsu, Maeda, Ken, Takahashi, Yoshimasa, Suzuki, Tadaki, Ohnishi, Makoto, Tanaka-Taya, Keiko
Format	Journal Article
Language	English
Published	Japan National Center for Global Health and Medicine 28.02.2023
Subjects	Original personal protective equipment risk factors seroepidemiology seroepidemiology risk factors personal protective equipment
Online Access	Get full text

Cover

Loading…

Abstract	As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers. We collected data on participants' sociodemographic characteristics, contact behaviors, installation status of personal protective equipment, and polymerase chain reaction testing results. We also collected whole blood and assessed seropositivity using the electrochemiluminescence immunoassay and microneutralization assay. In total, 161 (8.5%) of 1,899 participants were seropositive between August 3 and November 13, 2020. Physical contact (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.6) and aerosol-generating procedures (1.9, 1.1-3.2) were associated with seropositivity. Using goggles (0.2, 0.1-0.5) and N95 masks (0.3, 0.1-0.8) had a preventive effect. Seroprevalence was higher in the outbreak ward (18.6%) than in the COVID-19 dedicated ward (1.4%). Results showed certain specific risk behaviors of COVID-19; proper infection prevention practices reduced these risks.
AbstractList	As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers. We collected data on participants' sociodemographic characteristics, contact behaviors, installation status of personal protective equipment, and polymerase chain reaction testing results. We also collected whole blood and assessed seropositivity using the electrochemiluminescence immunoassay and microneutralization assay. In total, 161 (8.5%) of 1,899 participants were seropositive between August 3 and November 13, 2020. Physical contact (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.6) and aerosol-generating procedures (1.9, 1.1-3.2) were associated with seropositivity. Using goggles (0.2, 0.1-0.5) and N95 masks (0.3, 0.1-0.8) had a preventive effect. Seroprevalence was higher in the outbreak ward (18.6%) than in the COVID-19 dedicated ward (1.4%). Results showed certain specific risk behaviors of COVID-19; proper infection prevention practices reduced these risks. As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers. We collected data on participants' sociodemographic characteristics, contact behaviors, installation status of personal protective equipment, and polymerase chain reaction testing results. We also collected whole blood and assessed seropositivity using the electrochemiluminescence immunoassay and microneutralization assay. In total, 161 (8.5%) of 1,899 participants were seropositive between August 3 and November 13, 2020. Physical contact (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.6) and aerosol-generating procedures (1.9, 1.1-3.2) were associated with seropositivity. Using goggles (0.2, 0.1-0.5) and N95 masks (0.3, 0.1-0.8) had a preventive effect. Seroprevalence was higher in the outbreak ward (18.6%) than in the COVID-19 dedicated ward (1.4%). Results showed certain specific risk behaviors of COVID-19; proper infection prevention practices reduced these risks.As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate the risk of COVID-19 infection in healthcare workers. We collected data on participants' sociodemographic characteristics, contact behaviors, installation status of personal protective equipment, and polymerase chain reaction testing results. We also collected whole blood and assessed seropositivity using the electrochemiluminescence immunoassay and microneutralization assay. In total, 161 (8.5%) of 1,899 participants were seropositive between August 3 and November 13, 2020. Physical contact (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.6) and aerosol-generating procedures (1.9, 1.1-3.2) were associated with seropositivity. Using goggles (0.2, 0.1-0.5) and N95 masks (0.3, 0.1-0.8) had a preventive effect. Seroprevalence was higher in the outbreak ward (18.6%) than in the COVID-19 dedicated ward (1.4%). Results showed certain specific risk behaviors of COVID-19; proper infection prevention practices reduced these risks.
ArticleNumber	2022.01060
Author	Ohnishi, Makoto Kuroda, Yudai Nojima, Kiyoko Nagata, Noriyo Iida, Shun Fujimoto, Tsuguto Ueno, Takafumi Shimada, Tomoe Hasegawa, Mitsuru Suzuki, Motoi Moriyama, Saya Iwata-Yoshikawa, Naoko Kato, Kenichiro Sano, Kaori Takasugi, Kashiya Shimbashi, Reiko Okuma, Kazu Tanaka-Taya, Keiko Yuki, Hiroyoshi Fukushi, Shuetsu Arai, Satoru Maeda, Ken Takeda, Tomoko Koshida, Rie Shiino, Teiichiro Matsuzawa, Yukimasa Kato, Hirofumi Suzuki, Tadaki Kitaoka, Masami Yamada, Souichi Shimizu, Hidefumi Morino, Saeko Nakamura-Uchiyama, Fukumi Takanashi, Sayaka Takahashi, Yoshimasa Arashiro, Takeshi Ainai, Akira
Author_xml	– sequence: 1 fullname: Shimbashi, Reiko organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 2 fullname: Shiino, Teiichiro organization: Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan – sequence: 3 fullname: Ainai, Akira organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 4 fullname: Moriyama, Saya organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 5 fullname: Arai, Satoru organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 6 fullname: Morino, Saeko organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 7 fullname: Takanashi, Sayaka organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 8 fullname: Arashiro, Takeshi organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 9 fullname: Suzuki, Motoi organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 10 fullname: Matsuzawa, Yukimasa organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 11 fullname: Kato, Kenichiro organization: Nakanoegota Hospital, Nakano, Tokyo, Japan – sequence: 12 fullname: Hasegawa, Mitsuru organization: Okabe Hospital, Kanazawa, Ishikawa, Japan – sequence: 13 fullname: Koshida, Rie organization: Kanazawa City Health Center, Kanazawa, Ishikawa, Japan – sequence: 14 fullname: Kitaoka, Masami organization: Kanazawa City Health Center, Kanazawa, Ishikawa, Japan – sequence: 15 fullname: Ueno, Takafumi organization: Fukuoka Kinen Hospital, Fukuoka, Fukuoka, Japan – sequence: 16 fullname: Shimizu, Hidefumi organization: JCHO Tokyo Shinjuku Medical Center, Shinjuku, Tokyo, Japan – sequence: 17 fullname: Yuki, Hiroyoshi organization: Yamada Memorial Hospital, Sumida, Tokyo, Japan – sequence: 18 fullname: Takeda, Tomoko organization: Chuo Public Health Center, Chuo, Tokyo, Japan – sequence: 19 fullname: Nakamura-Uchiyama, Fukumi organization: Tokyo Metropolitan Bokutoh Hospital, Sumida, Tokyo, Japan – sequence: 20 fullname: Takasugi, Kashiya organization: Yoron Tokushukai Hospital, Oshima, Kagoshima, Japan – sequence: 21 fullname: Iida, Shun organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 22 fullname: Shimada, Tomoe organization: Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 23 fullname: Kato, Hirofumi organization: Department of Virology 1, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 24 fullname: Fujimoto, Tsuguto organization: Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 25 fullname: Iwata-Yoshikawa, Naoko organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 26 fullname: Sano, Kaori organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 27 fullname: Yamada, Souichi organization: Department of Virology 1, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 28 fullname: Kuroda, Yudai organization: Department of Veterinary Science, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 29 fullname: Okuma, Kazu organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan – sequence: 30 fullname: Nojima, Kiyoko organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan – sequence: 31 fullname: Nagata, Noriyo organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 32 fullname: Fukushi, Shuetsu organization: Department of Virology 1, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 33 fullname: Maeda, Ken organization: Department of Veterinary Science, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 34 fullname: Takahashi, Yoshimasa organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 35 fullname: Suzuki, Tadaki organization: Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 36 fullname: Ohnishi, Makoto organization: Deputy Director-General, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan – sequence: 37 fullname: Tanaka-Taya, Keiko organization: Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36865900$$D View this record in MEDLINE/PubMed
BookMark	eNp1kUtv3CAUha0qVZOmWXdXsezGEwwYm02ldtJHqkhZ9LFF18z1mMYGB5ipuuh_L5lJpg-pCwTinO9cxHlaHDnvsCieV3TB66Zh5-thWjDK2IJWVNJHxQkTXJSqUuLocG7lcXEWo-2oYKLiqqVPimMuW1krSk-Kn59mNLa3hiyvv15elJUiwcYb0uEAW-tDJOBWJA1I5oBbdMlukWDfo0nE92TGEL2DMas-5buderux85StBCbv1mRAGNNgICD57sNNJoh15CPM4J4Vj3sYI57d76fFl3dvPy8_lFfX7y-Xr69KIwVPJZM9gGlQ1nW9oqaXism24wJaptp-JWsUiilkspENSM6pYYCgRN92imLH-Wnxap87b7oJVyY_LsCo52AnCD-0B6v_Vpwd9NpvtVKNYKzNAS_vA4K_3WBMerLR4DiCQ7-JmjUtF0pwzrL1xZ-zDkMe_jwb6r3BBB9jwF4bmyBZfzfajrqielevzvXqu3r1rt7Mnf_DPUT_n3izJ77FBGs8-CEka0bc2Wtd5fUbOohmgKDR8V_5eMEw
CitedBy_id	crossref_primary_10_3390_vaccines11101527 crossref_primary_10_7759_cureus_77168
Cites_doi	10.1038/s41467-021-23233-6 10.1017/ice.2021.117 10.1016/j.eclinm.2021.100734 10.1016/S2214-109X(21)00026-7 10.1073/pnas.2002589117 10.3389/fmicb.2021.661187 10.1016/j.ijid.2021.01.013 10.1093/cid/ciaa287 10.1038/s41467-021-24115-7 10.1016/S1473-3099(20)30589-2 10.1001/jamanetworkopen.2020.31756 10.1016/j.jinf.2020.05.067 10.1371/journal.pone.0247865 10.1093/aje/kwaa191 10.3390/vaccines9080910 10.1017/ash.2021.255 10.1056/NEJMoa2026116 10.7554/eLife.60122 10.1016/j.jcv.2020.104437 10.1038/s41467-021-21111-9 10.1016/j.jvs.2020.07.040 10.1017/ice.2021.254 10.1093/cid/ciaa1684
ContentType	Journal Article
Copyright	2023 National Center for Global Health and Medicine 2023, National Center for Global Health and Medicine. 2023, National Center for Global Health and Medicine 2023
Copyright_xml	– notice: 2023 National Center for Global Health and Medicine – notice: 2023, National Center for Global Health and Medicine. – notice: 2023, National Center for Global Health and Medicine 2023
DBID	AAYXX CITATION NPM 7X8 5PM
DOI	10.35772/ghm.2022.01060
DatabaseName	CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Public Health
EISSN	2434-9194
EndPage	14
ExternalDocumentID	PMC9974228 36865900 10_35772_ghm_2022_01060 article_ghm_5_1_5_2022_01060_article_char_en
Genre	Journal Article
GroupedDBID	ALMA_UNASSIGNED_HOLDINGS JSF JSH RJT RPM RZJ AAYXX CITATION NPM 7X8 5PM
ID	FETCH-LOGICAL-c643t-26faac7e6555d0cf69268b34a8298fd65e4929e26767a6330c2aea94f8b90eb33
ISSN	2434-9186 2434-9194
IngestDate	Thu Aug 21 18:38:36 EDT 2025 Thu Jul 10 23:13:59 EDT 2025 Thu Jan 02 22:52:17 EST 2025 Thu Apr 24 23:09:53 EDT 2025 Tue Jul 01 03:36:53 EDT 2025 Sun Jul 28 06:07:40 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	seroepidemiology risk factors personal protective equipment
Language	English
License	2023, National Center for Global Health and Medicine.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c643t-26faac7e6555d0cf69268b34a8298fd65e4929e26767a6330c2aea94f8b90eb33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.jstage.jst.go.jp/article/ghm/5/1/5_2022.01060/_article/-char/en
PMID	36865900
PQID	2783494332
PQPubID	23479
PageCount	10
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9974228 proquest_miscellaneous_2783494332 pubmed_primary_36865900 crossref_citationtrail_10_35772_ghm_2022_01060 crossref_primary_10_35772_ghm_2022_01060 jstage_primary_article_ghm_5_1_5_2022_01060_article_char_en
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	20230228
PublicationDateYYYYMMDD	2023-02-28
PublicationDate_xml	– month: 2 year: 2023 text: 20230228 day: 28
PublicationDecade	2020
PublicationPlace	Japan
PublicationPlace_xml	– name: Japan
PublicationTitle	Global Health & Medicine
PublicationTitleAlternate	GHM
PublicationYear	2023
Publisher	National Center for Global Health and Medicine
Publisher_xml	– name: National Center for Global Health and Medicine
References	16. Roche Diagnostics K.K. Elecsys® Anti-SARS-CoV-2 RUO. https://diagnostics.roche.com/jp/ja/products/params/elecsys-anti-sars-cov-2.html (accessed August 6, 2022). (in Japanese) 15. Kato H, Seki K, Maeda Y, Noda Y, Iinuma Y, Kitaoka M, Kiso K, Koshida R, Kurosu H, Yamagishi T, Shimada T, Suzuki M, Sunagawa T. Rapid response to a coronavirus disease 2019 (COVID-19) outbreak in a psychiatry hospital-Kanazawa City, Japan, March to April 2020. Antimicrob Steward Healthc Epidemiol. 2022; 2:e57. 18. Ministry of Health, Labor and Welfare. Testing procedure of National Epidemiological Surveillance of Vaccine Preventable Diseases. https://www.niid.go.jp/niid/images/epi/yosoku/AnnReport/2021-99.pdf (accessed August 10, 2022). (in Japanese) 25. Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 and surface (fomite) transmission for indoor community environments. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-transmission.html (accessed March 30, 2022). 3. Sims MD, Maine GN, Childers KL, Podolsky RH, Voss DR, Berkiw-Scenna N, Oh J, Heinrich KE, Keil H, Kennedy RH, Homayouni R. Coronavirus disease 2019 (COVID-19) seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking. Clin Infect Dis. 2021; 73:S154-S162. 5. Tokyo Metropolitan Infectious Disease Surveillance Center. Number of cases by location of COVID-19 cluster. http://idsc.tokyo-eiken.go.jp/diseases/2019-ncov/ (accessed December 28, 2022). 28. Borremans B, Gamble A, Prager KC, Helman SK, McClain AM, Cox C, Savage V, Lloyd-Smith JO. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. Elife. 2020; 9:e60122. 26. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: A systematic review and meta-analysis. JAMA Netw Open. 2020; 3:e2031756. 8. The Japanese Association for Infectious Diseases. The 3rd COVID-19 Nosocomial Infection Questionnaire Survey. https://www.kansensho.or.jp/modules/news/index.php?content_id=318 (accessed December 28, 2022). (in Japanese) 13. Martischang R, Iten A, Arm I, Abbas M, Meyer B, Yerly S, Eckerle I, Pralong J, Sauser J, Suard JC, Kaiser L, Pittet D, Harbarth S. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: a large longitudinal cohort study. Infect Control Hosp Epidemiol. 2022; 43:326-333. 29. Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines. 2021; 9:910. 7. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19)‎ is suspected or confirmed. https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2021.1 (accessed December 31, 2022). 31. Yamayoshi S, Yasuhara A, Ito M, et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021; 32:100734. 35. Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, Ho SB. COVID-19 and healthcare workers: A systematic review and meta-analysis. Int J Infect Dis. 2021; 104:335-346. 2. Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. Lancet Infect Dis. 2020; 20:1401-1408. 4. World Health Organization. COVID-19 Weekly Epidemiological Update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2022 (accessed July 11, 2022). 14. Kwon S, Joshi AD, Lo CH, et al. Association of social distancing and face mask use with risk of COVID-19. Nat Commun. 2021; 12:3737. 33. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383:1724-1734. 1. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet. 2020; 395:1973-1987. 32. Goto A, Go H, Miyakawa K, et al. Sustained neutralizing antibodies 6 months following infection in 376 Japanese COVID-19 survivors. Front Microbiol. 2021; 12:661187. 27. Le Vu S, Jones G, Anna F, et al. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. Nat Commun. 2021; 12:3025. 24. Kurosu H, Watanabe K, Kurosawa K, et al. Possible contact transmission of SARS-CoV-2 in healthcare settings in Japan, 2020-2021. Infect Control Hosp Epidemiol. 2022; 43:1296-1298. 22. Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, Zheng N, Chen X, Lu W, Zhuang T, Yang J, Viboud C, Ajelli M, Leung DT, Yu H. Serological evidence of human infection with SARS-CoV-2: A systematic review and meta-analysis. Lancet Glob Health. 2021; 9:e598-609. 12. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk factors of healthcare workers with coronavirus disease 2019: A retrospective cohort study in a designated hospital of Wuhan in China. Clin Infect Dis. 2020; 71:2218-2221. 20. Ministry of Health, Labor and Welfare. The seroprevalence of SARS-CoV-2 in general public. https://www.mhlw.go.jp/content/000761671.pdf (accessed January 26, 2022). 17. Public Health England. Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunoassays. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation__of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf (accessed March 28, 2022). 23. Alkurt G, Murt A, Aydin Z, et al. Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey. PLoS One. 2021; 16:e0247865. 21. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, Cordes S, Ross B, Esser S, Lindemann M, Kribben A, Dittmer U, Witzke O, Herrmann A. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020; 128:104437. 6. National Institute of Infectious Diseases. Infection control measures for COVID-19. https://www.niid.go.jp/niid/images/epi/corona/2019nCoV-01-200602tbl.pdf (accessed October 2, 2022). 30. Marot S, Malet I, Leducq V, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021; 12:844. 10. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. Lancet Public Health. 2020; 5:e475-e483. 11. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, Yang H, Chen Y, Huang A, Liu Y, Chen Y, Yuan L, Yan X, Shen H, Wu C. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020; 81:420-426. 34. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in health-care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2021; 190:161-175. 19. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020; 117:7001-7003. 9. Ministry of Health, Labor and Welfare. COVID-19 information. https://covid19.mhlw.go.jp/en/ (accessed November 2, 2022). 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21
References_xml	– reference: 6. National Institute of Infectious Diseases. Infection control measures for COVID-19. https://www.niid.go.jp/niid/images/epi/corona/2019nCoV-01-200602tbl.pdf (accessed October 2, 2022). – reference: 32. Goto A, Go H, Miyakawa K, et al. Sustained neutralizing antibodies 6 months following infection in 376 Japanese COVID-19 survivors. Front Microbiol. 2021; 12:661187. – reference: 3. Sims MD, Maine GN, Childers KL, Podolsky RH, Voss DR, Berkiw-Scenna N, Oh J, Heinrich KE, Keil H, Kennedy RH, Homayouni R. Coronavirus disease 2019 (COVID-19) seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking. Clin Infect Dis. 2021; 73:S154-S162. – reference: 4. World Health Organization. COVID-19 Weekly Epidemiological Update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2022 (accessed July 11, 2022). – reference: 34. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in health-care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2021; 190:161-175. – reference: 25. Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 and surface (fomite) transmission for indoor community environments. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-transmission.html (accessed March 30, 2022). – reference: 27. Le Vu S, Jones G, Anna F, et al. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. Nat Commun. 2021; 12:3025. – reference: 31. Yamayoshi S, Yasuhara A, Ito M, et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021; 32:100734. – reference: 22. Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, Zheng N, Chen X, Lu W, Zhuang T, Yang J, Viboud C, Ajelli M, Leung DT, Yu H. Serological evidence of human infection with SARS-CoV-2: A systematic review and meta-analysis. Lancet Glob Health. 2021; 9:e598-609. – reference: 35. Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, Ho SB. COVID-19 and healthcare workers: A systematic review and meta-analysis. Int J Infect Dis. 2021; 104:335-346. – reference: 24. Kurosu H, Watanabe K, Kurosawa K, et al. Possible contact transmission of SARS-CoV-2 in healthcare settings in Japan, 2020-2021. Infect Control Hosp Epidemiol. 2022; 43:1296-1298. – reference: 2. Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. Lancet Infect Dis. 2020; 20:1401-1408. – reference: 16. Roche Diagnostics K.K. Elecsys® Anti-SARS-CoV-2 RUO. https://diagnostics.roche.com/jp/ja/products/params/elecsys-anti-sars-cov-2.html (accessed August 6, 2022). (in Japanese) – reference: 26. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: A systematic review and meta-analysis. JAMA Netw Open. 2020; 3:e2031756. – reference: 5. Tokyo Metropolitan Infectious Disease Surveillance Center. Number of cases by location of COVID-19 cluster. http://idsc.tokyo-eiken.go.jp/diseases/2019-ncov/ (accessed December 28, 2022). – reference: 15. Kato H, Seki K, Maeda Y, Noda Y, Iinuma Y, Kitaoka M, Kiso K, Koshida R, Kurosu H, Yamagishi T, Shimada T, Suzuki M, Sunagawa T. Rapid response to a coronavirus disease 2019 (COVID-19) outbreak in a psychiatry hospital-Kanazawa City, Japan, March to April 2020. Antimicrob Steward Healthc Epidemiol. 2022; 2:e57. – reference: 8. The Japanese Association for Infectious Diseases. The 3rd COVID-19 Nosocomial Infection Questionnaire Survey. https://www.kansensho.or.jp/modules/news/index.php?content_id=318 (accessed December 28, 2022). (in Japanese) – reference: 1. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ; COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet. 2020; 395:1973-1987. – reference: 30. Marot S, Malet I, Leducq V, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021; 12:844. – reference: 33. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383:1724-1734. – reference: 10. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. Lancet Public Health. 2020; 5:e475-e483. – reference: 13. Martischang R, Iten A, Arm I, Abbas M, Meyer B, Yerly S, Eckerle I, Pralong J, Sauser J, Suard JC, Kaiser L, Pittet D, Harbarth S. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: a large longitudinal cohort study. Infect Control Hosp Epidemiol. 2022; 43:326-333. – reference: 14. Kwon S, Joshi AD, Lo CH, et al. Association of social distancing and face mask use with risk of COVID-19. Nat Commun. 2021; 12:3737. – reference: 9. Ministry of Health, Labor and Welfare. COVID-19 information. https://covid19.mhlw.go.jp/en/ (accessed November 2, 2022). – reference: 18. Ministry of Health, Labor and Welfare. Testing procedure of National Epidemiological Surveillance of Vaccine Preventable Diseases. https://www.niid.go.jp/niid/images/epi/yosoku/AnnReport/2021-99.pdf (accessed August 10, 2022). (in Japanese) – reference: 29. Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines. 2021; 9:910. – reference: 7. World Health Organization. Infection prevention and control during health care when coronavirus disease (‎COVID-19)‎ is suspected or confirmed. https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2021.1 (accessed December 31, 2022). – reference: 11. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, Yang H, Chen Y, Huang A, Liu Y, Chen Y, Yuan L, Yan X, Shen H, Wu C. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020; 81:420-426. – reference: 21. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, Cordes S, Ross B, Esser S, Lindemann M, Kribben A, Dittmer U, Witzke O, Herrmann A. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020; 128:104437. – reference: 23. Alkurt G, Murt A, Aydin Z, et al. Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey. PLoS One. 2021; 16:e0247865. – reference: 12. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk factors of healthcare workers with coronavirus disease 2019: A retrospective cohort study in a designated hospital of Wuhan in China. Clin Infect Dis. 2020; 71:2218-2221. – reference: 17. Public Health England. Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunoassays. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/898437/Evaluation__of_sensitivity_and_specificity_of_4_commercially_available_SARS-CoV-2_antibody_immunoassays.pdf (accessed March 28, 2022). – reference: 20. Ministry of Health, Labor and Welfare. The seroprevalence of SARS-CoV-2 in general public. https://www.mhlw.go.jp/content/000761671.pdf (accessed January 26, 2022). – reference: 28. Borremans B, Gamble A, Prager KC, Helman SK, McClain AM, Cox C, Savage V, Lloyd-Smith JO. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. Elife. 2020; 9:e60122. – reference: 19. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020; 117:7001-7003. – ident: 27 doi: 10.1038/s41467-021-23233-6 – ident: 18 – ident: 4 – ident: 13 doi: 10.1017/ice.2021.117 – ident: 10 – ident: 31 doi: 10.1016/j.eclinm.2021.100734 – ident: 16 – ident: 22 doi: 10.1016/S2214-109X(21)00026-7 – ident: 19 doi: 10.1073/pnas.2002589117 – ident: 32 doi: 10.3389/fmicb.2021.661187 – ident: 35 doi: 10.1016/j.ijid.2021.01.013 – ident: 9 – ident: 7 – ident: 12 doi: 10.1093/cid/ciaa287 – ident: 14 doi: 10.1038/s41467-021-24115-7 – ident: 20 – ident: 2 doi: 10.1016/S1473-3099(20)30589-2 – ident: 17 – ident: 26 doi: 10.1001/jamanetworkopen.2020.31756 – ident: 5 – ident: 11 doi: 10.1016/j.jinf.2020.05.067 – ident: 23 doi: 10.1371/journal.pone.0247865 – ident: 34 doi: 10.1093/aje/kwaa191 – ident: 29 doi: 10.3390/vaccines9080910 – ident: 15 doi: 10.1017/ash.2021.255 – ident: 33 doi: 10.1056/NEJMoa2026116 – ident: 28 doi: 10.7554/eLife.60122 – ident: 21 doi: 10.1016/j.jcv.2020.104437 – ident: 6 – ident: 8 – ident: 30 doi: 10.1038/s41467-021-21111-9 – ident: 1 doi: 10.1016/j.jvs.2020.07.040 – ident: 24 doi: 10.1017/ice.2021.254 – ident: 25 – ident: 3 doi: 10.1093/cid/ciaa1684
SSID	ssib042413980 ssj0002512030 ssib044737821
Score	2.2264535
Snippet	As coronavirus disease 2019 (COVID-19) outbreaks in healthcare facilities are a serious public health concern, we performed a case-control study to investigate...
SourceID	pubmedcentral proquest pubmed crossref jstage
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	5
SubjectTerms	Original personal protective equipment risk factors seroepidemiology
Title	Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan
URI	https://www.jstage.jst.go.jp/article/ghm/5/1/5_2022.01060/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/36865900 https://www.proquest.com/docview/2783494332 https://pubmed.ncbi.nlm.nih.gov/PMC9974228
Volume	5
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
ispartofPNX	Global Health & Medicine, 2023/02/28, Vol.5(1), pp.5-14
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bixMxFA51FdkXUbzVGxF8EMrUTmYyF3wqq7IurD7YlX0bkmyyjWuntdsKK_jo__YkmWSmaxfUhw5lcppAvy8nJ8m5IPRCyBzMdMYic6sZpZzGEadSRbCY5IInIyFs-Njhh2z_KD04pse93q-O19J6xYfix9a4kv9BFd4BriZK9h-QDZ3CC_gO-MITEIbnX2Fsi8crLQZ7Hz-_fxPFpfMU96H358E9ctEkavruHTiso3Njhw-aXA229dtaL5zfua1CNG3dw4wHl4n21fXgAFbYumvWusoBjbRl0-U7-09TPeOmcJPDVJ_NOy3a1v8eTKTWYqqXoWmsa1cte3yml2H9OJwv9QWbMXegfcG6Bxck6QSCS6vgSJqkoGxdkWOvjekfpHOalW7T9wmFzQGgdDo1SQUIGZod7qgrCYAtZhb-JCsyUyK1XfiCO6JvuoauE-iQdA59zIJuTEDQhS4xlB3y1eaAu-im72LDvLnxBSz8U7lt83LZB7dj1Exuo1vNbgSPHbXuoJ6s76KfnlbY0wobWuFAKwy0wkAr3NIKO1rhucKeVrilFQ60wpZWuKUVbmiFdY0tre6ho3dvJ3v7UVOlIxJgza4ikinGRC4zSunJSKisJFnBk5QVpCzUSUZlCia4JCYzIMsSmP6ESVamquDlSPIkuY926nktHyJ8ElOVpzRWmYQFnBdlKmA_oFQZM8nB0uyjof9zK9GksDeVVL5WsJW1wFQATGWAqSwwffQy_GDhsrdcLfraoRUEm2lt5WgVw6eVDo0mNhJUUR899xBXoJ_NpRur5Xx9XtlKNqXJEthHDxzkYQRPmj7KN8gQBEzu982WWk9tDviyzE3yvkdX9vkY7baT7gnaWS3X8inYzyv-zLL7N5kUyok
linkProvider	National Library of Medicine
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Specific+COVID-19+risk+behaviors+and+the+preventive+effect+of+personal+protective+equipment+among+healthcare+workers+in+Japan&rft.jtitle=Global+health+%26+medicine&rft.au=Shimbashi%2C+Reiko&rft.au=Shiino%2C+Teiichiro&rft.au=Ainai%2C+Akira&rft.au=Moriyama%2C+Saya&rft.date=2023-02-28&rft.eissn=2434-9194&rft.volume=5&rft.issue=1&rft.spage=5&rft_id=info:doi/10.35772%2Fghm.2022.01060&rft_id=info%3Apmid%2F36865900&rft.externalDocID=36865900
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2434-9186&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2434-9186&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2434-9186&client=summon